MILPITAS, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- TurnOnGreen, Inc. (OTC: TOGI) (“TurnOnGreen” or the “Company”) and its power solutions subsidiary, Digital Power Corporation (“DPC”), today announced a major expansion of their telecommunications power product line, highlighted by a significant order from a global leader in network connectivity infrastructure. The order covers advanced power systems engineered for broadband, cable TV network, and data center applications, underscoring DPC’s growing presenc ...

SOMERSET, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Wednesday, November 12, 2025, to review third quarter 2025 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay of ...

Feedonomics customers benefit from data optimized for and exported to key AI channels. Select BigCommerce customers can now access agentic checkout with PayPal's agentic commerce servicesAUSTIN, Texas, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Commerce (Nasdaq: CMRC), an open, intelligent ecosystem of technology solutions and the parent company of leading ecommerce platform BigCommerce and AI-enriched product feed management solution Feedonomics, today announced a new agentic commerce feature with seamless agentic ...

Media Release Pivotal TACTI-004 (KEYNOTE-F91) Phase III trial evaluating eftilagimod alfa (efti) in first line non-small cell lung cancer continues to build momentum and is recruiting patients at a growing number of activated clinical sites and countriesTrial in Progress poster for TACTI-004 presented at the World Conference on Lung Cancer (WCLC) 2025, where physician feedback continued to be encouragingPositive feedback received from the FDA regarding future late-stage clinical development of efti in first ...

MIAMI, NEW YORK and WASHINGTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Siebert Financial Corp. (NASDAQ: SIEB) today announced the opening of a Washington, D.C. office to support its expanding Capital Markets and Investment Banking team. Located at 3000 K Street, N.W., Suite 245, Washington, D.C., the new office will be led by Daniel M. Ondeck, Head of Institutional Sales, who works closely with Siebert’s investment bankers on origination and execution across public and private markets, as well as by newly appoin ...

Core Insights - Hyperion DeFi has announced a strategic partnership with Felix to utilize 500,000 HYPE for launching a custom on-chain perpetual futures market, marking a significant advancement in decentralized finance [1][2][3] Group 1: Partnership and Product Development - The HYPE Asset Use Service (HAUS) agreement allows Hyperion DeFi to support Felix in managing a new market using the HIP-3 framework, which facilitates the creation of markets for non-crypto assets [2][3] - This partnership is expected to expand Hyperliquid's product offerings and user base while generating new revenue streams from staked HYPE assets [3][4] Group 2: Market Performance and Future Plans - Felix has achieved a total value locked (TVL) of over $1 billion as of September 2025, indicating strong market traction [4][11] - Felix plans to further integrate its DeFi infrastructure into the development of Felix Exchange, aiming to enhance liquidity access and stablecoin minting [4][5] Group 3: Hyperliquid Platform and HYPE Token - Hyperliquid is a next-generation blockchain designed for high-frequency trading, featuring on-chain perpetual futures and spot order books with rapid transaction times [6] - The HYPE token serves as the native currency of Hyperliquid, with over 30 million HYPE autonomously purchased and sequestered by the blockchain as of October 2025 [7][8]

CUPERTINO, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in Spartan Capital Securities Second Annual Investor Conference on November 3, 2025, in ...

SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Wednesday, November 5, 2025, at 8:30 a.m. EST to report its third quarter 2025 financial results and recent corporate highlights. To particip ...

New lighting technology delivers full-spectrum, Far Red, and UV light beneath canopy to increase yield, boost flavor, enhance aroma, and improve overall flower quality for commercial cultivatorsDENVER, Oct. 29, 2025 (GLOBE NEWSWIRE) -- GrowGeneration Corp. (NASDAQ: GRWG) (“GrowGen” or the “Company”), the nation’s largest specialty hydroponic and organic gardening retailer, today announced the launch of its Dialed In™ Tri-Spec Under Canopy Light, a first-of-its-kind lighting solution engineered to boost lowe ...

Core Insights - Belite Bio Inc is a clinical-stage drug development company focused on novel therapeutics for degenerative retinal diseases with significant unmet medical needs [3] Group 1: Company Overview - Belite Bio is advancing therapeutics targeting conditions such as STGD1 and GA in advanced dry AMD, as well as specific metabolic diseases [3] - The company's lead candidate, Tinlarebant, is an oral therapy aimed at reducing bisretinoid toxin accumulation in the eye [3] - Tinlarebant is currently being evaluated in multiple studies: a Phase 3 study (DRAGON), a Phase 2/3 study (DRAGON II) for adolescent STGD1 subjects, and a Phase 3 study (PHOENIX) for subjects with GA [3] Group 2: Upcoming Events - The executive management team will present at the Deutsche Bank ADR Virtual Investor Conference on November 4, 2025, at 10:30 am ET [1] - A webcast of the presentation will be available on the conference website, with a replay accessible for 90 days post-presentation [2]